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Abstract
Background: Parasomnia overlap disorder (POD) is a distinct parasomnia and characterized by concomitant
manifestation of rapid-eye-movement (REM)- and non-REM (NREM)-parasomnias. Although not uncommon among
patients with Parkinson’s disease, POD is often under-investigated.
Case presentation: This is the first report of patients with PD and features of POD that underwent deep brain
stimulation. Our patients exhibited different outcomes of POD features after subthalamic deep brain stimulation.
Conclusions: We expect that the reporting of these first patients will open the discussion about the need for more
detailed and broad-spectrum assessments regarding parasomnias in PD patients that undergo deep brain
stimulation. The implications of our observations are both clinical and neurobiological.
Keywords: Overlap parasomnia, Non-REM parasomnia, REM sleep behavior disorder, Sleep, Deep brain stimulation,
Parkinson’s disease
Background
Parasomnia overlap disorder (POD) is a distinct para-
somnia and characterized by concomitant manifestation
of rapid-eye-movement (REM)- and non-REM (NREM)-
parasomnias. There are only limited data on the preva-
lence of POD in the course of Parkinson’s disease (PD),
and a previous questionnaire-based study reported that
26 out of 417 (6%) PD patients reported sleepwalking
and also features of REM behavior disorder (RBD), sug-
gesting the presence of POD. [1] To the best of our
knowledge, this is the first report of PD patients with
POD features in the context of subthalamic deep brain
stimulation (STN-DBS).
Methods
Standard video-polysomnography (v-PSG) was per-
formed in all presented cases as previously described. [1]
The v-PSG consisted of six channel EEG (F3/A2, F4/A1,
C3/A2, C4/A1, O1/A2, O2/A1), left and right
electrooculography, submental, left and right anterior
tibialis, flexor carpi radialis and adductor digiti minimi
electromyography, electrocardiography, respiratory flow
and effort, and pulse-oximetry. All recordings were per-
formed by Embla RemLogic™ Software. Sleep stages and
sleep-associated events were manually scored according
to the ICSD-III [2].
Levodopa equivalent daily dose (LEDD) was calculated
as previously described (including all commonly used
medications in PD patients such as dopamine agonists,
MAO-B inhibitors, COMT-inhibitors etc.) [3].
Case presentations
Case 1
Patient 1, female, age 70 was diagnosed in 1999 with
tremor-dominant PD, underwent bilateral STN-DBS in
2015. Since 2012, the quality of sleep gradually deterio-
rated mainly due to disrupted night sleep and early
morning awakening resulting in daytime sleepiness
(Epworth Sleepiness Scale, ESS:12/24). She reported
weekly sleep-talking but no sleep-walking or dream-
enacting behavior (DEB).
In v-PSG prior to STN-DBS, quantification of EMG-
activity [4] showed increased phasic/tonic muscle activity
and several episodes of DEB during REM-sleep. NREM-
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parasomnia included repeated mumbling, sleep-talking
and confusional arousals.
STN-DBS was well received and 1 year after surgery,
motor signs, assessed by Unified Parkinson’s Disease
Rating Scale (UPDRS) part III, were ameliorated (57%)
and LEDD was reduced by 91% (from 885 mg to 75 mg).
Pregabaline 50 mg (prescribed due to very mild restless
legs symptoms) and quetiapine 25 mg were gradually
stopped after DBS surgery. The rest of medication
(levothyroxine and painkillers) remained unchanged.
Sleep quality and daytime sleepiness (ESS 5/24) im-
proved and sleep-talking became rare. Sleep architecture
improved markedly (Fig. 1, a1–2). Awakenings from stage
3 NREM were present but showed no episodes of DEB or
confusional arousals. Compared to baseline, EMG showed
a 44% reduction in tonic and 8% reduction in phasic activ-
ity. Apnea–Hypopnea Index (AHI) improved from 19.2/h
to 9.2/h.
At the time of postoperative assessments stimulation
parameters were:
STN (right): monopolar stimulation, C + 9-, 60 msec
pulse width, 2.5 V amplitude and 125 Hz repetition /
STN (left): interleave stimulation, a) C + 1-, 2.2 V (2.0–
3.4 V) amplitude, 60 msec pulse width, 125 Hz repeti-
tion and b) C + 0-, 60 msec pulse width, 2.5 V ampli-
tude, 125 Hz repetition.
Case 2
Patient two, male, age 75, was diagnosed with rigid-
hypokinetic PD in 2002, underwent bilateral STN-DBS
in 2015. He reported refreshing sleep of good quality, no
insomnia and only minor daytime sleepiness (ESS 7/24).
His wife reported occasional episodes of sleep-walking,
sleep-talking and DEB.
v-PSG prior to STN-DBS revealed increased phasic/
tonic muscle activity [4] and several episodes of DEB
during REM sleep as well as NREM-parasomnia includ-
ing bruxismus, movements of all four extremities, sleep-
talking, sounds of laughing/crying and grimacing several
times throughout the night.
STN-DBS was well received and 1 year after surgery,
motor signs, assessed by UPDRS part III, improved
(50%) and LEDD was reduced by 70% (from 1500 mg to
460 mg). The rest of the medication (painkillers)
remained unchanged. Sleepiness slightly improved (ESS
3/24), however, sleep quality deteriorated and his wife
reported that frequency of sleepwalking and DEB dou-
bled after DBS. In v-PSG, sleep architecture showed no
significant changes (Fig. 1, b1–2). During REM sleep,
while tonic activity was reduced (from 36 to 15% of total
REM sleep), phasic activity increased (from 22 to 28%).
During stage 3 NREM, episodes of confusional arousal
were captured. AHI changed from 7/h to 2/h.
Fig. 1 Polysomnography. a Hypnogram prior to surgery (1) showing a reduced sleep latency (1 min), low percentage of slow wave and REM
sleep, increased NREM stage 1 sleep and arousal index of 33.3/h. One year after STN-DBS (2) sleep architecture improved with normal sleep latency
(21 min), less frequent arousals (arousal index of 12.4/h), normal distribution of sleep stages and several REM-NREM cycles (Stimulation on).
b Hypnogram prior to surgery (1) showing a reduced sleep latency (1.5 min), low percentage of slow wave NREM3 sleep (2.5%), one
long-lasting and one very short-lasting phase of REM and normal NREM stage 1 sleep and arousal index of 33.9/h. One year after STN-DBS (2) sleep
architecture improved slightly with normal sleep latency (17 min), less frequent arousals (arousal index of 8.6/h), normal distribution of sleep stages
and 3 REM-NREM cycles (Stimulation on). c Hypnograms after STN-DBS showing the progression of the initially moderate disrupted sleep architecture
in 2012 (1) into ambiguous sleep and status dissociatus in 2016 (2). In 2016, scoring of REM sleep was based on the presence of “saw tooth waves” in
EEG and REM despite the absence of muscle atonia (Stimulation on). Time in hours: minutes on the x-axis. Sleep stages on y-axis: stage W (wake),
stages S1-S3 (NREM), and stage R (REM)
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At the time of postoperative assessments stimulation
parameters were:
STN (right): bipolar stimulation, 9–10+, 5.5 V (4.9–
6.1 V) amplitude, 60 msec pulse width, 130 Hz repetition
/STN (left): bipolar stimulation, 2–3+, 4.5 V (4.5–5.1 V)
amplitude, 60 msec pulse width, 130 Hz repetition.
Case 3
Patient three, male, age 55, diagnosed with tremor-
dominant PD in 1994, underwent bilateral STN-DBS in
2003. Prior to STN-DBS, LEDD was 900 mg and sleep
quality was poor (no sleep scores available).
After STN-DBS, motor signs improved (85% in UPDRS
part III), sleep-wake functions remained unchanged and
he remained free from dopaminergic medication until
2010 (at that time stimulation parameters were: STN
(right): monopolar stimulation, C + 1-, 2.5Volt, 60 msec
pulse width, and 145 Hz repetition/STN (left): monopolar
stimulation, C + 1-, 3.5 V, 60 msec pulse width, 145 Hz
repetition). Since 2010, LEDD was gradually increased
from 0 mg to 560 mg (2013) and to 635 mg (2016) while
the dose of venlafaxine 150 mg daily remained unchanged
between 2010 and 2015 (2015 increased to a 300 mg
dose). No anticholinergic drugs were given.
Since 2012, sleep quality progressively deteriorated,
daytime sleepiness worsened (in 2012 ESS 07/24, in
2016 ESS 12/24), DEB frequency increased (previously
only rare episodes were reported) and he developed
prominent insomnia. Nocturnal behavior was character-
ized by sudden movements, unintelligible sounds and
falling out of bed associated with vivid dreams and
sleep-walking (2×/week).
v-PSGs in 2012 and 2014 illustrated a progressive in-
crement in phasic/tonic muscle activity during REM
sleep. NREM-parasomnia in 2012 included axial myoclo-
nus, mumbling, sleep-talking, chewing, and spitting. In
2016, v-PSG showed a status dissociatus with constant
movements of all extremities, sleep-talking, laughing,
grimacing and tongue-clicking throughout the whole
night (Fig. 1, c1–2). DEB-episodes coincided with “saw
tooth waves” in EEG and REM, without associated
muscle atonia. AHI gradually increased from normal in
2012 to 10/h in 2014 and 19/h in 2016.
At the time of 2016 postoperative assessments, stimu-
lation parameters were:
STN (right): monopolar stimulation, C + 1-, 2.6 V
amplitude, 60 msec pulse width, and 140 Hz repetition/
STN (left): monopolar stimulation, C + 2-, 3.0 V, 90 msec
pulse width, 130 Hz repetition.
Discussion and Conclusions
DBS is a well-established treatment for motor symptoms
in PD. Despite the impact of sleep disturbances on quality
of life of patients with PD, [5] only few DBS studies
included sleep and polysomnographic assessments prior
to and after surgery (for review see Eugster et al. [6]).
Considering sleep-wake functions as an integral part of
the DBS outcome in PD patients, we report the first
three PD patients with features of POD that underwent
STN-DBS.
The pathological substrate of POD in PD remains un-
clear. Previous studies implicated neurodegeneration at
the brainstem, possibly Lewy pathology, [7] involving the
ascending control of state transition and the descending
control of muscle tone. [8] At the neural level, gross
motor phenomena during REM or NREM sleep may arise
from a dissociated activity between serotonergic neurons
that modulate tonic motor activity and those in the raphe
nuclei regulating REM-NREM states, [9] implicating sero-
tonergic system in the motor activity during REM and
NREM sleep that characterizes POD. Changes in sleep
quality and behavior after STN-DBS can be attributed to
improved mobility or respiration and changes in medica-
tion. However, STN-related neuronal pathways may also
directly be involved in sleep physiology mainly through re-
ciprocal projections to structures involved in generation
and modulation of sleep stages (including raphe nucleus,
pedunculopontine nucleus and laterodorsal tegmentum),
[10–12] and to regions that regulate circadian rhythms,
mainly the thalamus [13, 14].
In the presented cases, it is difficult to disentangle the
impact of STN-DBS, medication and disease progression
itself on POD outcome. In cases 1 and 2, the very different
course regarding outcome of POD features after STN-
DBS underlies the important role of DBS itself or even dif-
ferences in the stimulation parameters (e.g. bipolar vs
monopolar stimulation) since in both cases there was a
prominent LEDD reduction (90% and 70% respectively)
and a comparable improvement in motor signs. In case 3,
the alterations in sleep behavior, including deterioration of
sleep quality, progressive development of POD and status
dissociatus were observed only several years after STN-
DBS and 2 years after readmission of dopaminergic ther-
apy, underlying the important role of disease progression
and possibly of the medication.
We expect that the reporting of these first patients will
open the discussion about the need for more detailed
and broad-spectrum assessments regarding parasomnias
in PD patients that undergo DBS, with the goal of in-
cluding these assessments in future prospective studies.
This, not only will advance pre-DBS selection proce-
dures, it will contribute to the improvement of postoper-
ative therapeutic practice and may give new insights into
the neurobiology of motor and sleep-wake control.
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